Brief report: Variant of hepatitis B virus with primary resistance to adefovir

被引：172

作者：

Schildgen, O

Sirma, H

Funk, A

Olotu, C

Wend, UC

Hartmann, H

Helm, M

Rockstroh, JK

Willems, WR

Will, H

Gerlich, WH

机构：

[1] Univ Bonn, Inst Med Microbiol & Immunol, D-5300 Bonn, Germany

[2] Univ Bonn, Dept Med 1, D-5300 Bonn, Germany

[3] Heinrich Pette Inst, Hamburg, Germany

[4] Inst Med Virol, D-35392 Giessen, Germany

[5] Practice Gastroenterol & Hepatol, Herne, Germany

[6] Practice Abelein Helm, Nurnberg, Germany

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2006年 / 354卷 / 17期

关键词：

D O I：

10.1056/NEJMoa051214

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The reverse-transcriptase inhibitor lamivudine ( Zeffix, GlaxoSmithKline) is often treat chronic infection with hepatitis B virus ( HBV) until resistance develops. may then be switched to the reverse-transcriptase inhibitor adefovir Gilead), which has a lower frequency of resistance. Here, we describe cases of primary adefovir resistance that were sensitive to tenofovir ( Viread, All three cases involved a rare HBV variant with a valine at position 233 of transcriptase domain instead of isoleucine ( rtI233V), as in the wild-type This HBV variant also displayed resistance to adefovir and sensitivity to tenofovir vitro.

引用

页码：1807 / 1812

页数：6

共 27 条

[21] Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region [J].